Apollo Endosurgery (NASDAQ:APEN) is set to release its earnings data after the market closes on Thursday, November 8th. Analysts expect Apollo Endosurgery to post earnings of ($0.34) per share for the quarter.
Apollo Endosurgery (NASDAQ:APEN) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.10). Apollo Endosurgery had a negative net margin of 46.55% and a negative return on equity of 58.61%. The firm had revenue of $15.79 million for the quarter, compared to analyst estimates of $16.56 million. On average, analysts expect Apollo Endosurgery to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of APEN stock traded up $0.08 during trading hours on Wednesday, reaching $6.08. 100 shares of the stock traded hands, compared to its average volume of 55,184. Apollo Endosurgery has a 1-year low of $3.75 and a 1-year high of $9.65. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.87 and a quick ratio of 2.18. The firm has a market capitalization of $124.49 million, a P/E ratio of -3.02 and a beta of 0.34.
In other news, major shareholder Stonepine Capital, L.P. purchased 300,000 shares of the business’s stock in a transaction dated Friday, November 2nd. The shares were acquired at an average price of $5.00 per share, for a total transaction of $1,500,000.00. Following the completion of the acquisition, the insider now directly owns 2,877,996 shares of the company’s stock, valued at $14,389,980. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 52.80% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Apollo Endosurgery (APEN) to Release Quarterly Earnings on Thursday” was published by WKRB News and is the property of of WKRB News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.wkrb13.com/2018/11/07/apollo-endosurgery-apen-to-release-quarterly-earnings-on-thursday.html.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope.
Recommended Story: Consumer behavior in bull markets
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.